Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or the “Company”), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that, pursuant to the authorisation received from the Company's Extraordinary General Meeting on 20 February 2017 and the financing arrangement entered into with Bracknor Investment and the Finnish Innovation Fund Sitra which was announced on 21 July 2016, the Board of Directors of the Company has today resolved on issuing 3,524,756 new shares to Sitra with an aggregate subscription price of EUR 499,999.95 based on the stand-by equity distribution agreement (SEDA). The new shares will be listed approximately on 21 March 2017. After the issuance the total number of registered shares in the Company will be 77,586,747.
Martin Jamieson, Chairman and CEO
Martin Jamieson, Chief Executive Officer
UB Securities Oy (Certified Adviser)
+358 (0)9 2538 0246
Citigate Dewe Rogerson
+44 (0)207 2821066
About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.